Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promotor (CeTeG/NOA 09): a randomised, open-label, phase 3 trial.
Herrlinger U, Tzaridis T, Mack F et al.
Lancet 2019;393: 678 – 688